Leiden University Scholarly Publications

Your Search

Enabled Filters

  • (-) = Velde, C.J.H. van de
  • (-) = Fontein, D.B.Y.
  • (-) ≠ breast cancer

Search results

  • RSS Feed
(1 - 20 of 23)

Pages

Specific adverse events are associated with response to exemestane therapy in postmenopausal breast cancer patients: Results from the TEAMIIA study (BOOG2006-04)
Fontein, D.B.Y.; Charehbili, A.; Nortier, J.W.R.; Putter, H.; Kranenbarg, E.M.K.; Kroep, J.R.; ... ; Velde, C.J.H. van de 2017
Specific adverse events are associated with response to exemestane therapy in postmenopausal breast cancer patients: Results from the TEAMIIA study (BOOG2006-04)
Article / Letter to editor
metadata only
Long term effects of extended adjuvant endocrine therapy on quality of life in breast cancer patients
Kool, M.; Fontein, D.B.Y.; Kranenbarg, E.M.K.; Nortier, J.W.R.; Rutgers, E.J.T.; Marang-van de Mheen, P.J.; Velde, C.J.H. van de 2015
Long term effects of extended adjuvant endocrine therapy on quality of life in breast cancer patients
Article / Letter to editor
metadata only
Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients - A phase II trial
Fontein, D.B.Y.; Charehbili, A.; Nortier, J.W.R.; Kranenbarg, E.M.K.; Kroep, J.R.; Putter, H.; ... ; Velde, C.J.H. van de 2014
Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients - A phase II trial
Article / Letter to editor
metadata only
Germline variants in the CYP19A1 gene are related to specific adverse events in aromatase inhibitor users: a substudy of Dutch patients in the TEAM trial
Fontein, D.B.Y.; Houtsma, D.; Nortier, J.W.R.; Baak-Pablo, R.F.; Kranenbarg, E.M.K.; Straaten, T.R.J.H.M. van der; ... ; Guchelaar, H.J. 2014
Germline variants in the CYP19A1 gene are related to specific adverse events in aromatase inhibitor users: a substudy of Dutch patients in the TEAM trial
Article / Letter to editor
metadata only
Relationship between specific adverse events and clinical response to neoadjuvant exemestane therapy in postmenopausal breast cancer patients: Preliminary results from the TEAM IIA trial (BOOG 2004-06)
Charehbili, A.; Fontein, D.B.Y.; Linn, S.C.; Kranenbarg, A.E.M.K.; Kroep, J.R.; Liefers, G.J.; ... ; Velde, C.J.H. van de 2014
Relationship between specific adverse events and clinical response to neoadjuvant exemestane therapy in postmenopausal breast cancer patients: Preliminary results from the TEAM IIA trial (BOOG 2004-06)
Article / Letter to editor
metadata only
Neoadjuvant hormonal therapy for endocrine sensitive breast cancer: A systematic review
Charehbili, A.; Fontein, D.B.Y.; Kroep, J.R.; Liefers, G.J.; Mieog, J.S.D.; Nortier, J.W.R.; Velde, C.J.H. van de 2014
Neoadjuvant hormonal therapy for endocrine sensitive breast cancer: A systematic review
Article / Letter to editor
metadata only
Age and the effect of physical activity on breast cancer survival: A systematic review
Fontein, D.B.Y.; Glas, N.A. de; Duijm, M.; Bastiaannet, E.; Portielje, J.E.A.; Velde, C.J.H. van de; Liefers, G.J. 2013
Age and the effect of physical activity on breast cancer survival: A systematic review
Article / Letter to editor
metadata only
Symptoms and Cancer Outcome in Adjuvant Endocrine Therapy for Breast Cancer: Why Are They Associated? Reply
Fontein, D.B.Y.; Velde, C.J.H. van de; Int Tamoxifen Exemestane Adjuvant 2013
Symptoms and Cancer Outcome in Adjuvant Endocrine Therapy for Breast Cancer: Why Are They Associated? Reply
Article / Letter to editor
metadata only
Response to: Timing of the sentinel lymph node biopsy in breast cancer patients receiving neoadjuvant therapy - Recommendations for clinical guidance
Fontein, D.B.Y.; Water, W. van de; Hezewijk, M. van; Velde, C.J.H. van de 2013
Response to: Timing of the sentinel lymph node biopsy in breast cancer patients receiving neoadjuvant therapy - Recommendations for clinical guidance
Article / Letter to editor
metadata only
Upfront adjuvant aromatase inhibitors in women with lobular breast cancer response
Water, W. van de; Fontein, D.B.Y.; Velde, C.J.H. van de 2013
Upfront adjuvant aromatase inhibitors in women with lobular breast cancer response
Article / Letter to editor
metadata only
Immunological subtypes in breast cancer are prognostic for invasive ductal but not for invasive lobular breast carcinoma
Fontein, D.B.Y.; Engels, C.C.; Bastiaannet, E.; Kruijf, E.M. de; Liefers, G.J.; Nortier, J.W.R.; ... ; Kuppen, P.J.K. 2013
Immunological subtypes in breast cancer are prognostic for invasive ductal but not for invasive lobular breast carcinoma
Article / Letter to editor
metadata only
Preliminary results of the TEAMIIA trial: Efficacy of six months neoadjuvant exemestane therapy in postmenopausal hormone receptor-positive breast cancer patients - a Dutch Breast Cancer Trialists' Group study
Fontein, D.B.Y.; Charehbili, A.; Kranenbarg, W.M.M.K.; Linn, S.C.; Liefers, G.J.; Kroep, J.R.; ... ; Velde, C.J.H. van de 2013
Preliminary results of the TEAMIIA trial: Efficacy of six months neoadjuvant exemestane therapy in postmenopausal hormone receptor-positive breast cancer patients - a Dutch Breast Cancer Trialists' Group study
Article / Letter to editor
metadata only
Pre- and postdiagnostic physical activity levels in relation to breast cancer outcome in postmenopausal breast cancer patients - results of the TEAM-lifestyle study
Glas, N.A. de; Fontein, D.B.Y.; Bastiaannet, E.; Pijpe, A.; Craen, A.J.M. de; Liefers, G.J.; ... ; Leeuwen, F.E. van 2013
Pre- and postdiagnostic physical activity levels in relation to breast cancer outcome in postmenopausal breast cancer patients - results of the TEAM-lifestyle study
Article / Letter to editor
metadata only
Accuracy of treatment response assessment modalities after neoadjuvant therapy: A Dutch Breast Cancer Trialists' Group (BOOG) substudy
Charehbili, A.; Fontein, D.B.Y.; Smit, V.T.; Wasser, M.N.; Leeuwen-Stok, A.E. van; Kranenbarg, E.M.M.K.; ... ; Kroep, J.R. 2013
Accuracy of treatment response assessment modalities after neoadjuvant therapy: A Dutch Breast Cancer Trialists' Group (BOOG) substudy
Article / Letter to editor
metadata only
Specific Adverse Events Predict Survival Benefit in Patients Treated With Tamoxifen or Aromatase Inhibitors: An International Tamoxifen Exemestane Adjuvant Multinational Trial Analysis
Fontein, D.B.Y.; Seynaeve, C.; Hadji, P.; Hille, E.T.M.; Water, W.V. de; Putter, H.; ... ; Velde, C.J.H. van de 2013
Specific Adverse Events Predict Survival Benefit in Patients Treated With Tamoxifen or Aromatase Inhibitors: An International Tamoxifen Exemestane Adjuvant Multinational Trial Analysis
Article / Letter to editor
metadata only
Timing of the sentinel lymph node biopsy in breast cancer patients receiving neoadjuvant therapy - Recommendations for clinical guidance
Fontein, D.B.Y.; Water, W. van de; Mieog, J.S.D.; Liefers, G.J.; Velde, C.J.H. van de 2013
Timing of the sentinel lymph node biopsy in breast cancer patients receiving neoadjuvant therapy - Recommendations for clinical guidance
Article / Letter to editor
metadata only
Influence of semi-quantitative oestrogen receptor expression on adjuvant endocrine therapy efficacy in ductal and lobular breast cancer - A TEAM study analysis
Water, W. van de; Fontein, D.B.Y.; Nes, J.G.H. van; Bartlett, J.M.S.; Hille, E.T.M.; Putter, H.; ... ; Velde, C.J.H. van de 2013
Influence of semi-quantitative oestrogen receptor expression on adjuvant endocrine therapy efficacy in ductal and lobular breast cancer - A TEAM study analysis
Article / Letter to editor
metadata only
Quality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side study
Nes, J.G.H. van; Fontein, D.B.Y.; Hille, E.T.M.; Voskuil, D.W.; Leeuwen, F.E. van; Haes, J.C.J.M. de; ... ; Velde, C.J.H. van de 2012
Quality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side study
Article / Letter to editor
metadata only
ER Allred Score Predicts Outcome of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer - a TEAM Study Analysis
Water, W. van de; Fontein, D.B.Y.; Bartlett, J.M.S.; Putter, H.; Robson, T.; Seynaeve, C.; ... ; Velde, C.J.H. van de 2012
ER Allred Score Predicts Outcome of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer - a TEAM Study Analysis
Article / Letter to editor
metadata only
High non-compliance in the use of letrozole after 2.5years of extended adjuvant endocrine therapy. Results from the IDEAL randomized trial
Fontein, D.B.Y.; Nortier, J.W.R.; Liefers, G.J.; Putter, H.; Meershoek-Klein Kranenbarg, E.; Bosch, J. van den; ... ; Velde, C.J.H. van de 2012
High non-compliance in the use of letrozole after 2.5years of extended adjuvant endocrine therapy. Results from the IDEAL randomized trial
Article / Letter to editor
metadata only
AIMS The aim of this study was to investigate non-compliance to aromatase inhibitors and factors associated with early treatment discontinuation in the extended adjuvant setting. METHODS The IDEAL... Show moreAIMS The aim of this study was to investigate non-compliance to aromatase inhibitors and factors associated with early treatment discontinuation in the extended adjuvant setting. METHODS The IDEAL trial is a prospective, open-label phase-III trial comparing 2.5 with 5 years of extended adjuvant letrozole (LET) in hormone receptor positive (HR+) postmenopausal early breast-cancer patients after 5 years of adjuvant endocrine therapy (ET). The purpose of this study was to assess non-compliance in the first 2.5 years of extended adjuvant therapy. Non-compliance was defined as early discontinuation of LET for all reasons, excluding death or recurrence. RESULTS At 2.5 years, 1215 patients were included in the analysis. Overall non-compliance probability was 18.4%, of which 85.1% discontinued due to toxicities. Analyses showed that patients with prior sequential therapy were less likely to discontinue treatment than when treated with AI or TAM upfront (logrank p = 0.004). Longer treatment-free intervals also predicted more non-compliance (logrank p = 0.011). Age was not predictive of non-compliance (p = 0.571). Prior surgery (mastectomy vs breast conserving surgery), both with or without radiotherapy and/or chemotherapy were also not associated with early treatment discontinuation (p = 0.228 and p = 0.585 respectively). Although having fewer than four positive lymph nodes predicted more non-compliance (logrank p = 0.050), age, tumor type and locoregional treatment did not. CONCLUSIONS High non-compliance to extended ET was confirmed. Toxicities were the major reason for discontinuation, and this was not influenced by age. Longer treatment-free intervals and fewer positive lymph nodes predicted more non-compliance. Patients who underwent sequential therapy were least likely to discontinue extended adjuvant ET. Show less

Pages